CLASS II ONGOING Drug recall · Reported 20 Aug 2025 · FDA Enforcement Report

Carvedilol Tablets, USP, 5 mg recalled by Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Inc., U is recalling Carvedilol Tablets, USP, 5 mg per, distributed nationwide in the US. The recall was initiated on 6 Aug 2025 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: 17241257, 17241258, 17241279, Exp. Date 06/2026
NDC68462-162, 68462-163, 68462-164, 68462-165
UPC0368462162019, 0368462163016, 0368462164013, 0368462165010
Quantity recalled17, 496 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0587-2025
FDA event ID
97372
Recalling firm
Glenmark Pharmaceuticals Inc., U, Mahwah, NJ
Manufacturer
Glenmark Pharmaceuticals Inc., USA
Classification
Class II
Status
Ongoing
Recall initiated
6 Aug 2025
FDA classified
14 Aug 2025
Reported
20 Aug 2025
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity

Timeline

6 Aug 2025Recall initiated by company
14 Aug 2025Classified by FDA+8 days
20 Aug 2025Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Carvedilol Tablets, USP, 12.5 mg, 500 Tablets per carton, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot No. 2, Phase-2, Pharma Zone SEZ, Pithampur, Dist.-Dhar, Madhya Pradesh 454 775, India. Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 47430, NDC 68462-164-05

Where it was distributed

Nationwide within the USA

Nationwide

Questions about this recall

Is Carvedilol Tablets, USP, 5 mg per recalled?

Yes. Glenmark Pharmaceuticals Inc., U recalled Carvedilol Tablets, USP, 5 mg per on 6 Aug 2025. The recall is Class II and its status is Ongoing. Recall number D-0587-2025.

Why was it recalled?

CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm

Which lots are affected?

Lot #: 17241257, 17241258, 17241279, Exp. Date 06/2026

Where was it sold?

Nationwide within the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Glenmark Pharmaceuticals Inc., U

All 141

Other Carvedilol recalls

All 19